Test in Focus
T-cell lymphoma is a term used to describe a group of cancers derived from T cells, which are cells of the immune system that play a critical role in immune function. T-cell lymphoma is not a single disease, but rather a name given to a wide variety of diseases that have different pathologic and clinical features.
With more than 30 identified subtypes of T-cell lymphoma in existence, making an accurate, definitive diagnosis can be difficult. In addition to an extensive IHC and FISH test offerings, Mayo Clinic’s hematopathology team not only has extensive experience detecting and diagnosing T-cell neoplasms, but also frequently provides T-cell lymphoma consultations for clients around the globe to help give clinicians the diagnostic answers they need to effectively treat T-cell lymphoma patients.
“The most common molecular assays that we do right now are T-cell receptor gene rearrangement studies for clonality,” says clinical hematopathologist Andrew Feldman, M.D. “And that's often used to differentiate between clonal or neoplastic processes and reactive processes.”
Learn more by listening to the below “Test in Focus” episode of our “Answers From the Lab” podcast with Dr. Feldman.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.
Joseph Maleszewski, M.D., and Marie-Christine Aubry, M.D., explain how Mayo Clinic Laboratory can provide definitive diagnosis of primary ciliary dyskinesia (PCD). Mayo Clinic's expertise and technology have earned the laboratory's designation as the sole center of excellence for diagnosing this rare respiratory disorder.
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.